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ABSTRACT 38 
Background: Cough is recognised as an important troublesome symptom in the diagnosis 39 
and monitoring of asthma. Asthma control is thought to be determined by the degree of 40 
airway inflammation and hyper-responsiveness but how these relate to cough frequency is 41 
unclear. 42 
Objective: To investigate the relationships between objective cough frequency, disease 43 
control, airflow obstruction and airway inflammation in asthma.  44 
Methods: Participants with asthma underwent 24 hour ambulatory cough monitoring, 45 
exhaled nitric oxide, spirometry, methacholine challenge and sputum induction (cell counts 46 
and inflammatory mediator levels). Asthma control was assessed by GINA classification 47 
and the Asthma Control Questionnaire (ACQ).  48 
Results: Eighty-nine subjects with asthma (mean age 57 years (±SD 12); 57% female) 49 
were recruited. According to GINA criteria, 18 (20.2%) patients were classified as 50 
controlled, 39 (43.8%) partly controlled and 32 (36%) uncontrolled; median (range) ACQ 51 
score was 1 (0.0-4.4). ACQ-6 correlated with 24hr cough frequency (r=0.40; p<0.001) and 52 
patients with uncontrolled asthma (GINA) had higher median 24hr cough frequency 53 
(4.2c/h, range 0.3-27.6) compared with partially controlled and controlled asthma (1.8c/h, 54 
range 0.2-25.3 and 1.7c/h range 0.3-6.7, p=0.01 and p=0.002 respectively). Measures of 55 
airway inflammation were not significantly different between GINA categories and were not 56 
correlated with ACQ. In multivariate analyses, increasing cough frequency and worsening 57 
FEV1 independently predicted measures of asthma control. 58 
Conclusion: Ambulatory cough frequency monitoring provides an objective assessment of 59 
asthma symptoms that correlates with standard measures of asthma control, but not 60 
airflow obstruction or airway inflammation. Moreover, cough frequency and airflow 61 
obstruction represent independent dimensions of asthma control. 62 
63 
INTRODUCTION 64 
Asthma is a chronic inflammatory disease of the airways, estimated to affect 300 million 65 
people worldwide1. The aim of asthma treatment is to achieve and maintain control of the 66 
clinical manifestations of asthma; this includes current symptoms but also reducing the risk 67 
of future exacerbations. However despite an increase in our understanding of the 68 
mechanisms underlying asthma and the availability of effective treatments, optimal asthma 69 
control is often not achieved2. Several tools are currently in use for describing asthma 70 
control; a categorical classification based on expert opinion has been suggested by the 71 
Global Initiative for Asthma (GINA) and clinical trials have commonly used the Asthma 72 
Control Questionnaire (ACQ)3 which gives a numerical score and is responsive to 73 
treatment4-6. These tools rely on patient recall of symptom frequency, severity, and 74 
medication use over several weeks. Such reporting is inevitably influenced by a range of 75 
external factors unrelated to asthma, for example, vigilance, mood, and social interactions, 76 
as well as memory. A more objective measure of asthma symptoms may therefore be a 77 
useful tool for assessing control and treatment responses.  78 
Cough is an important symptom in asthma because it predicts disease severity7, 8 , poor 79 
prognosis9, and is a common10 troublesome symptom11. Unlike wheezing, breathlessness 80 
and chest tightness, coughing is readily objectively quantified using ambulatory monitoring 81 
systems12. We have previously shown that objective cough counts are elevated in asthma 82 
patients compared with healthy controls, but are poorly represented by patient reports of 83 
cough13. However, it is not known whether the objective measurement of cough frequency 84 
is a useful marker of asthma control. Furthermore, it is unknown whether cough frequency 85 
is related to elements of asthma pathophysiology such as airflow obstruction and 86 
inflammation. Therefore, the aim of this study was to examine in a group of patients with 87 
asthma not selected for cough, the relationships between objective cough frequency, 88 
asthma control (GINA classification and ACQ) and measures of airway obstruction and 89 
inflammation. 90 
 91 
MATERIALS AND METHODS 92 
Subjects 93 
We studied subjects with asthma recruited from a longitudinal cohort of adult asthma 94 
patients established in 199714, 15. Inclusion criteria were: physician diagnosis of asthma, 95 
age ≥16 years, symptoms of asthma in the preceding 12 months and minimum treatment 96 
with a short-acting bronchodilator. Ethical approval was obtained from the regional 97 
Research Ethics Committee (06/Q1403/110) and subjects provided written informed 98 
consent. 99 
Study Procedures 100 
All subjects attended the North West Lung Research Centre, University Hospital of South 101 
Manchester on two occasions, at least one week apart and within a two week period. Prior 102 
to both visits subjects withheld medication as follows: short acting bronchodilators for six 103 
hours; long acting bronchodilators, theophyllines and leukotriene receptor antagonists for 104 
12 hours; antihistamines and inhaled steroid for 48 hours.  105 
At visit 1, subjects performed exhaled nitric oxide (eNO) (NIOX, Aerocrine, Sweden) 106 
followed by spirometry (Jaeger Viasys Healthcare, Germany) and reversibility of forced 107 
expiratory volume in one second (FEV1) to 400µg salbutamol determined according to 108 
American Thoracic Society criteria16. Reversible airflow obstruction was defined by an 109 
increase in FEV1 of ≥12%. Sputum was induced using 3%, 4% and 5% saline sequentially 110 
via an ultrasonic nebulizer (Sonix 2000, Clement Clarke, Harlow, UK). Samples were 111 
processed as previously described17. A total of 400 non-squamous cells were counted by a 112 
fully trained observer and were expressed both as a percentage and as a number of cells 113 
per gram of selected sputum. Competitive or sandwich ELISA’s were performed to 114 
measure inflammatory mediators; leukotriene B4 (LTB4), prostaglandin E2 (PGE2) 8-115 
isoprostane (8-iso) and leukotriene C4 (LTC4), interleukin-8 (IL-8), myeloperoxidase (MPO) 116 
and eosinophilic cationic protein (ECP). Subjects completed the Asthma Control 117 
Questionnaire (ACQ-7)3. Subjects were categorised into levels of control according to 118 
GINA guidelines using information given in questionnaires, clinical history and pulmonary 119 
function. Finally, subjects underwent ambulatory 24 hour cough monitoring using the 120 
VitaloJAK cough recorder as previously described18, 19.Recordings were analysed using an 121 
audio editing package (Audition 3.0, Adobe systems Inc., San Jose, CA). The number of 122 
cough sounds was manually counted and expressed as coughs per hour (c/h).  123 
At visit 2, bronchial hyper-responsiveness (BHR) was assessed using the 5-breath 124 
dosimeter method (KoKo, Ferraris, Hertford, UK) according to published guidelines, and 125 
defined by the dose causing a 20% drop from baseline FEV1 in response to methacholine 126 
(PD20)20 . Skin Prick Testing was performed and atopy was defined by the presence of at 127 
least one positive skin prick test to common inhaled allergens (House dust mite, cat, dog, 128 
grass, mixed moulds)  129 
 130 
Statistical Analysis 131 
Data were analysed using SPSS Version 20.0 (IBM Corp., NY). Overall 24 hour and 132 
daytime cough rates were log transformed prior to analysis and geometric mean (95%CI) 133 
summary data given. Spearman rank correlations were used throughout. Non-parametric 134 
data were compared using the Mann- Whitney U test. Multinomial logistic regression and 135 
general linear models were used to investigate possible predictors of GINA control 136 
category and ACQ score respectively. Only parameters correlated with control in the 137 
univariate analysis (p<0.1) were included in the models and non-statistically significant 138 
variables were sequentially removed from each model to determine the model which 139 
explained the greatest proportion of variance in asthma control. As the ACQ-7 includes a 140 
score for % predicted FEV1, (that would inevitably be correlated with the % predicted 141 
FEV1), we opted to also use the ACQ-6 score for the general linear models, which only 142 
includes scores for symptoms and reliever medication use. 143 
  144 
RESULTS 145 
Subjects 146 
We studied 89 subjects with asthma, summarised in Table 1. Out of 88 subjects who 147 
underwent reversibility testing (one subject with β2-agonist intolerance not tested), 23 148 
(26.1%) had bronchodilator reversibility, and 37 (50.7%) of 73 subjects tested had a 149 
positive methacholine challenge; testing was not carried out in 16 subjects (three subjects 150 
did not attend; one subject refused; two subjects had used a β2-agonist and 10 subjects 151 
were below the FEV1 safety cut-off for the test). A total of 45 subjects had bronchodilator 152 
reversibility and/or positive methacholine challenge, and 32 (44% of those tested) had 153 
neither. Subjects were evenly distributed between British Thoracic Society (BTS) Steps 1-154 
4 (e-Table 1).  155 
Asthma Control 156 
According to GINA criteria, 18 (20.2%) patients were classified as controlled, 39 (43.8%) 157 
were partly controlled and 32 (36%) uncontrolled. GINA category was not influenced by 158 
gender but uncontrolled patients were older than partly controlled and controlled (62.4yrs 159 
(±9.0) versus 54.8(±12.1) and 54(±13.7), p=0.019). ACQ-7 data were available for 88 160 
(98.9%) subjects [median (range) score 1 (0.0-4.4)]. There was also a correlation between 161 
ACQ score and age (r=0.22; p=0.04). Uncontrolled patients were treated with higher doses 162 
of ICS (p<0.001) and there was a positive correlation between ACQ score and ICS dose (r 163 
= 0.39, p<0.001). Smoking status did not influence measures of asthma control (ACQ 164 
score or GINA control). 165 
Objective Cough Rates 166 
Ambulatory cough monitoring was performed in 86 subjects. Night time data was missing 167 
in four patients due to battery failure. Cough rate varied widely between subjects 168 
[geometric mean (95% CI) 2.5 c/h (0.2-27.6)] and were higher by day than by night 169 
[median day (range) 3.7 c/h, (0.2 – 41.3) night 0.5 (0-29.6), p<0.001]. There were no 170 
gender differences in cough frequency (log 24hour cough rate), nor was this influenced by 171 
age, BMI, FEV1 percentage predicted, log eNO or dose-response ratio to methacholine.  172 
There was a tendency for the small number of current smokers to have a higher cough 173 
frequency than ex-smokers or non-smokers (p=0.09). Thirteen subjects were on ACE 174 
inhibitors but cough frequency was not raised in these patients (ACE inhibitor geometric 175 
mean 2.8c/h [95% CI 1.5-5.2] versus no ACE inhibitor 2.4c/h [1.8-3.2]); p=0.64). 176 
Airway Inflammation 177 
The geometric mean of eNO was 23.2 ppb (95% CI 19.9-27.1). There was a negative 178 
correlation between eNO and ICS dose (r=-0.29; p=0.007). 179 
Induced sputum data were available for 55 (61.8%) subjects. The inter-observer 180 
agreement for counts of 400 non squamous cells were: eosinophil mean difference 3.3 181 
cells (equivalent to 0.8% of total count; 95% CI -9.5 to 16.0), and neutrophil mean 182 
difference 7.6 cells (equivalent to 1.9% of total count; 95% CI -41.5 to 56.6). Geometric 183 
mean of percentage sputum eosinophils was 2.1% (95% CI 1.5-2.9) and a median 184 
0.11x10-6 cells/g of sputum (IQR 0.01-0.11x10-6). A total of 30 (54.5%) subjects had 185 
increased sputum eosinophils (i.e. ≥2%). Median percentage of sputum neutrophils was 186 
68% (57.3-77.3) with 2.25 x10-6 cells/g of sputum (IQR 0.76-2.96 x10-6).  187 
Levels of airway inflammatory mediators were measured in subjects with satisfactory cell 188 
counts, see e-Table 2. There were correlations between sputum ECP levels and 189 
eosinophil counts (percentage: r=0.43, p=0.002) as well as between sputum IL-8 and 190 
neutrophils (percentage: r=0.44, p=0.001). There were no significant correlations between 191 
objective cough frequency and sputum eosinophils or neutrophils (e-Table 3). For sputum 192 
inflammatory mediators only 8-isoprostane showed a correlation with objective cough 193 
frequency (e-Table 4). 194 
 195 
Predictors of Asthma Control 196 
GINA Categories  197 
Cough frequency and FEV1 significantly differed between GINA categories (p=0.003, 198 
p<0.001 respectively), see Figure 1A and B. Subjects in the uncontrolled group had higher 199 
cough rates than both partially controlled (p=0.01), and controlled (p=0.002). This was also 200 
the case for daytime cough counts, (p=0.004 and p=0.002) and nocturnal cough counts 201 
(p=0.004 and p=0.04). Subjects with uncontrolled asthma had greater airflow obstruction 202 
than both partly controlled (p=0.002) and controlled (p<0.001). Although sputum 203 
eosinophils increased with worsening asthma control, the differences between groups did 204 
not reach statistical significance (Figure 1D). There were no statistically significant 205 
differences in sputum neutrophils (% or cells x106/g sputum) (Figure 1C), levels of airway 206 
inflammatory mediators (e-Table 5), methacholine challenge or log eNO between GINA 207 
control categories.  208 
In a multinomial logistic regression model with GINA control category as the outcome 209 
variable, higher log 24hr cough frequency (p<0.001) and lower % FEV1 (p<0.001) were 210 
independently predictive of GINA category. Numbers in each group were too small for 211 
odds ratios to be calculated. 212 
Asthma Control Questionnaire (ACQ) 213 
There were positive correlations between ACQ-6 and 24hr cough frequency (r=0.40; 214 
p<0.001) (see Figure 2), daytime cough rate, (r=0.40; p<0.001) and overnight cough rate 215 
(r=0.30; p=0.006). There was a correlation between ACQ-6 and logeNO (r=0.24, p=0.03) 216 
and borderline correlation with % predicted FEV1 (r=-0.19, p=0.07). There were no 217 
statistically significant correlations between ACQ-6 and percentage sputum 218 
eosinophils/neutrophils (% or cells x106/g sputum) (see table 2), inflammatory mediators, 219 
or methacholine challenge (data not shown). 220 
In the general linear model, log ACQ-6 was only significantly predicted by log 24hr cough 221 
rate (p=0.008) which accounted for 17% of the variance. When the model was repeated 222 
with ACQ-7 (including % predicted FEV1) as the outcome variable, log total cough rate 223 
(p=0.004) and FEV1 percent predicted (p=0.001) independently predicted asthma control, 224 
accounting for 37% of the variance. 225 
 226 
DISCUSSION 227 
Until recently, few studies have sought to objectively quantify cough in patients with 228 
asthma. Our previous work found objective measures of cough were poorly represented by 229 
subjective patient reporting of cough severity and were also not related to standard 230 
measures of asthma such as FEV1, methacholine responsiveness or eNO.13 To the best of 231 
our knowledge, this study is the first to examine the relationships between objective cough 232 
frequency, asthma control, airflow obstruction, and airway inflammation. We have 233 
demonstrated that increasing cough rates are associated with worse asthma control as 234 
assessed by both the GINA criteria and the ACQ score. In addition, we found that 235 
objective cough frequency and airflow obstruction independently predicted disease control, 236 
whereas measures of airway inflammation did not. 237 
Bronchial hyper-responsiveness (BHR) and airway inflammation are acknowledged as 238 
important components of asthma pathophysiology but how they relate to asthma control is 239 
less clear. Previously published data suggest BHR and inflammation do not discriminate 240 
well between different levels of asthma control21, 22. Furthermore, treatment algorithms 241 
which incorporate measures of sputum eosinophils23, 24 or BHR 25 to titrate treatment, 242 
improved exacerbation rates and reduced airway re-modelling respectively, but failed to 243 
show improvements in asthma control. Similarly disappointing were the outcomes based 244 
on eNO algorithms when used as an adjunct or as an alternative to standard clinical 245 
management26-28; at best, only a reduction in the inhaled steroid dose was achieved. 246 
Together these observations suggest that there may be other important determinants of 247 
day to day asthma control. 248 
This study is consistent with a cluster analysis of asthmatics29 which showed some groups 249 
of asthmatics demonstrated discordance between airway inflammation and symptoms, i.e. 250 
high levels of symptoms despite low levels of eosinophilic inflammation (discordant 251 
symptoms) or high levels of eosinophilic inflammation but low expression of symptoms 252 
(discordant inflammation). Our data relating symptoms to inflammatory cells and mediators 253 
similarly failed to show any overall relationship, even when the symptom of cough was 254 
quantified objectively and for mediators with known tussive effects, e.g. PGE2. This data 255 
would therefore suggest that inflammation does not directly trigger asthma symptoms and 256 
that other mechanisms may play an important role. Airway nerves are crucial to the 257 
development of symptoms such as cough, shortness of breath, chest tightness and pain. 258 
These symptoms are dependent on nerve activation and transmission to the central 259 
nervous system predominantly via vagal afferents, hence, these symptoms are blocked or 260 
inhibited by vagal anaesthesia or transection30. We speculate that neuronal dysfunction in 261 
asthma could be the missing link in explaining the discordance between airway 262 
inflammation and symptoms.  263 
We set out to study a ‘real life’ asthma population and inclusion criteria for the study 264 
reflected this; patients had a physician diagnosis of asthma but were not selected for 265 
cough, reversibility or BHR as a pre-requisite. However, subjects were recruited from a 266 
previously established much larger ASMAL (ASsessment of Manchester Asthmatics 267 
Longitudinally) cohort established in 1996 where over 88% had evidence of BHR at 268 
baseline31. Over 80% of our patients were established on inhaled corticosteroid treatment 269 
and the sensitivity of methacholine challenge in the diagnosis of asthma is reduced by 270 
taking this treatment32. Furthermore, compared with the tidal breathing method, the 5 271 
breath dosimeter method may underestimate BHR due to the protective bronchodilator 272 
effect of deep breathing33. Finally, although this study found an association between 273 
objective cough frequency and asthma control, further interventional studies would be 274 
required to confirm objective cough frequency is a useful and sensitive marker of improved 275 
control.  276 
 277 
CONCLUSIONS 278 
Data from this study suggest objective measurements of cough provide unique information 279 
about asthma control, not fully captured by ACQ or GINA questionnaires. Importantly 280 
cough frequency reflected asthma control independent of airflow obstruction and 281 
inflammation. The inclusion of measures of cough frequency in future asthma studies 282 
offers an objective measure of day to day control that may be better for assessing the 283 
impact of novel asthma therapies.   284 
ACKNOWLEDGEMENTS 285 
Guarantor statement: Professor Jacky Smith is the guarantor of the content of this 286 
manuscript, including data and analysis. 287 
Author’s contributions: Concept and design; P.M, I.S, B.I, A.A.W, N.C.T, S.J.F, J.A.S. 288 
Data generation; P.M, B.I, L.Y, L.J, I.D. Statistical analysis and modelling; P.M, I.S and 289 
J.A.S. All authors reviewed the manuscript and approved the final draft. 290 
Financial/non-financial disclosures: P.M, I.S, B.I, L.Y, I.D, L.J, N.C.T, S.J.F have no 291 
conflicts of interests directly related to this study. A.A.W and J.A.S are named inventors on 292 
a patent, owned by UHSM, describing a method for generating output data licensed to 293 
Vitalograph Ltd, however, no financial benefits have been received.  294 
Role of the Sponsor: No input in design, analysis or in manuscript writing. 295 
Other contributions: We thank Dr Elizabeth Juniper for permission to use the Asthma 296 
Control Questionnaire (ACQ) in this study. 297 
Additional information: The e-Tables can be found in the Supplemental Materials section 298 
of the online article. 299 
  300 
References 301 
1. (GINA) GIfA. GINA Report. Global Strategy for Asthma Management and 302 
Prevention. Revised 2012. 2012. 303 
2. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al. Asthma control 304 
in Europe: a real-world evaluation based on an international population-based 305 
study. J Allergy Clin Immunol 2007; 120:1360-7. 306 
3. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and 307 
validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-308 
7. 309 
4. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al. 310 
Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in 311 
moderate asthma. Am J Respir Crit Care Med 2007; 175:228-34. 312 
5. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma 313 
control during the year after bronchial thermoplasty. N Engl J Med 2007; 356:1327-314 
37. 315 
6. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of 316 
a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory 317 
asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63:584-318 
91. 319 
7. Mincheva R, Ekerljung L, Bjerg A, Axelsson M, Popov TA, Lundback B, et al. 320 
Frequent cough in unsatisfactory controlled asthma--results from the population-321 
based West Sweden Asthma study. Respir Res 2014; 15:79. 322 
8. de Marco R, Marcon A, Jarvis D, Accordini S, Almar E, Bugiani M, et al. Prognostic 323 
factors of asthma severity: a 9-year international prospective cohort study. J Allergy 324 
Clin Immunol 2006; 117:1249-56. 325 
9. Thomson NC, Chaudhuri R, Messow CM, Spears M, MacNee W, Connell M, et al. 326 
Chronic cough and sputum production are associated with worse clinical outcomes 327 
in stable asthma. Respir Med 2013; 107:1501-8. 328 
10. Manfreda J, Becklake MR, Sears MR, Chan-Yeung M, Dimich-Ward H, Siersted 329 
HC, et al. Prevalence of asthma symptoms among adults aged 20-44 years in 330 
Canada. CMAJ 2001; 164:995-1001. 331 
11. Osman LM, McKenzie L, Cairns J, Friend JA, Godden DJ, Legge JS, et al. Patient 332 
weighting of importance of asthma symptoms. Thorax 2001; 56:138-42. 333 
12. Sumner H, Woodcock A, Kolsum U, Dockry R, Lazaar AL, Singh D, et al. Predictors 334 
of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir 335 
Crit Care Med 2013; 187:943-9. 336 
13. Marsden PA, Smith JA, Kelsall AA, Owen E, Naylor JR, Webster D, et al. A 337 
comparison of objective and subjective measures of cough in asthma. J Allergy Clin 338 
Immunol 2008; 122:903-7. 339 
14. Langley SJ, Goldthorpe S, Craven M, Morris J, Woodcock A, Custovic A. Exposure 340 
and sensitization to indoor allergens: association with lung function, bronchial 341 
reactivity, and exhaled nitric oxide measures in asthma. J Allergy Clin Immunol 342 
2003; 112:362-8. 343 
15. Langley SJ, Goldthorpe S, Craven M, Woodcock A, Custovic A. Relationship 344 
between exposure to domestic allergens and bronchial hyperresponsiveness in 345 
non-sensitised, atopic asthmatic subjects. Thorax 2005; 60:17-21. 346 
16. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General 347 
considerations for lung function testing. Eur Respir J 2005; 26:153-61. 348 
17. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum 349 
to investigate airway inflammation. Thorax 1997; 52:498-501. 350 
18. Decalmer SC, Webster D, Kelsall AA, McGuinness K, Woodcock AA, Smith JA. 351 
Chronic cough: how do cough reflex sensitivity and subjective assessments 352 
correlate with objective cough counts during ambulatory monitoring? Thorax 2007; 353 
62:329-34. 354 
19. Kelsall A, Decalmer SC, McGuinness K, Woodcock A, Smith JA. Sex differences 355 
and predictors of objective cough frequency in chronic cough. Thorax 2009. 356 
20. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. 357 
Guidelines for methacholine and exercise challenge testing-1999. This official 358 
statement of the American Thoracic Society was adopted by the ATS Board of 359 
Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309-29. 360 
21. Volbeda F, Broekema M, Lodewijk ME, Hylkema MN, Reddel HK, Timens W, et al. 361 
Clinical control of asthma associates with measures of airway inflammation. Thorax 362 
2013; 68:19-24. 363 
22. Quaedvlieg V, Sele J, Henket M, Louis R. Association between asthma control and 364 
bronchial hyperresponsiveness and airways inflammation: a cross-sectional study in 365 
daily practice. Clin Exp Allergy 2009; 39:1822-9. 366 
23. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. 367 
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. 368 
Lancet 2002; 360:1715-21. 369 
24. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, et al. 370 
Determining asthma treatment by monitoring sputum cell counts: effect on 371 
exacerbations. Eur Respir J 2006; 27:483-94. 372 
25. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. 373 
Clinical control and histopathologic outcome of asthma when using airway 374 
hyperresponsiveness as an additional guide to long-term treatment. The AMPUL 375 
Study Group. Am J Respir Crit Care Med 1999; 159:1043-51. 376 
26. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, et al. 377 
Management of asthma based on exhaled nitric oxide in addition to guideline-based 378 
treatment for inner-city adolescents and young adults: a randomised controlled trial. 379 
Lancet 2008; 372:1065-72. 380 
27. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric 381 
oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 382 
352:2163-73. 383 
28. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, et al. The 384 
use of exhaled nitric oxide to guide asthma management: a randomized controlled 385 
trial. Am J Respir Crit Care Med 2007; 176:231-7. 386 
29. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster 387 
analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 388 
178:218-24. 389 
30. Widdicombe J. Lung afferent activity: implications for respiratory sensation. Respir 390 
Physiol Neurobiol 2009; 167:2-8. 391 
31. Langley SJ, Goldthorpe S, Custovic A, Woodcock A. Relationship among 392 
pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of 393 
asthmatic patients. Ann Allergy Asthma Immunol 2003; 91:398-404. 394 
32. Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, et al. 395 
Methacholine challenge test: diagnostic characteristics in asthmatic patients 396 
receiving controller medications. J Allergy Clin Immunol 2012; 130:69-75 e6. 397 
33. Prieto L, Lopez V, Llusar R, Rojas R, Marin J. Differences in the response to 398 
methacholine between the tidal breathing and dosimeter methods: influence of the 399 
dose of bronchoconstrictor agent delivered to the mouth. Chest 2008; 134:699-703. 400 
 401 
 402 
403 
Tables 404 
 405 
Table 1 Subject Characteristics 406 
 407 
Characteristic Asthma 
Subjects (n=89) 
Age, years* 57.3 (±11.9) 
Gender, % Female 57.3 
BMI, kg/m2* 28.6 (±5.3) 
Smoker, % Never 52.8 
Ex  39.3 
Current 7.9 
Pack Year History** 0.0 (0.0-67.5) 
Asthma Duration. Years** 29.0 (10.0-68.0) 
Atopy 83.5% 
FEV1, % predicted* 86.4 (±22.1) 
ICS Dose, µg BDP** 800 (0-4000) 
 408 
Data quoted as * mean (±SD); ** median (range) 409 
410 
Table 2: Correlation between ACQ-6, cough rates and sputum cell counts 411 
 412 
Parameter ACQ-6 
Cough rate 
(coughs/hour, 
c/h) 
Day r=0.40 
p<0.001 
Night r=0.30 
p=0.006 
Total r=0.40 
p<0.001 
Sputum cell 
counts 
Eosinophil % r=0.12 
p=0.37 
cells x106.g 
sputum 
r=0.12 
p=0.37 
Neutrophil % r=-0.10 
p=0.45 
cells x 106/g 
sputum 
r=-0.10 
p=0.45 
All correlations Spearman Rank 413 
414 
FIGURE LEGENDS 415 
Figure 1: Comparison of controlled, partially controlled and uncontrolled asthma patients 416 
(GINA classification) A) Objective cough frequency over 24hrs; B) FEV1 percent predicted; 417 
C) Percent sputum neutrophils and D) Percent sputum eosinophils. 418 
Figure 2:  Correlation between ACQ-6 score and total cough rate (c/hr) 419 
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Supplementary Results 20 
e-Table 1: Patient therapy according to British Thoracic Society Asthma Treatment 21 
Steps 22 
 23 
BTS 
Treatment 
Step 
1 Inhaled short-acting β2-agonist as required 22.5% 
2 ICS 200-800 mcg/day 27.0% 
3 ICS plus inhaled long-acting β2-agonist 24.7% 
4 
ICS up to 2000 mcg/day and /or addition of a fourth 
drug e.g. leukotriene receptor antagonist, or slow-
release theophylline, 
β2-agonist tablet 
24.7% 
5 Systemic corticosteroids 1.1% 
 24 
  25 
e-Table 2: Sputum Inflammatory Mediator Levels in Asthma Subjects  26 
Inflammatory 
Mediator in Sputum 
 
Asthma 
LTB4 (pg/ml) 
 
816.4 (240.4-6063.2) 
n=55 
 
PGE2 (pg/ml) 2331.0 (669.0-6032.0) 
n=55 
 
8-Iso (pg/ml) 43.4 (17.8-373.6) 
n=55 
 
LTC4 (pg/ml) 447.2 (8.0-2624.0) 
n=55 
 
IL-8 (pg/ml) 852.4 (94.8-4400.0) 
n=54 
 
ECP (ng/ml) 101.2 (1.2-220.0) 
n=53 
 
MPO (ng/ml) 118.7 (1.0-446.4) 
n=54 
 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
e-Table 3: Correlations between sputum cell types and objective cough rates 40 
in subjects with asthma.  41 
Parameter Daytime 
Cough Rate 
Night time 
Cough Rate 
Overall 
Cough Rate 
Eosinophil % 
 
r=0.13 
p=0.37 
r=0.17 
p=0.21 
r=0.16 
p=0.26 
cells x 10-6/g 
sputum 
r=0.12 
p=0.41 
r=0.19 
p=0.16 
r=0.14 
p=0.31 
Neutrophil % 
 
r=-0.10 
p=0.47 
r=-0.01 
p=0.92 
r=-0.09 
p=0.50 
cells x 10-6/g 
sputum 
r=-0.07 
p=0.63 
r=0.10 
p=0.47 
r=-0.06 
p=0.66 
All correlations Spearman Rank   42 
e-Table 4: Correlations between Cough Rates and Sputum Inflammatory 43 
Mediators in Asthma Subjects 44 
 45 
Mediator 
 
Daytime Cough 
Rate 
Night time Cough 
Rate 
Total Cough Rate 
LTB4 
 
r=0.08 
p=0.55 
r=0.13 
p=0.37 
r=0.09 
p=0.54 
 
PGE2 
 
 
r=-0.19 
p=0.17 
r=-0.02 
p=0.89 
r=-0.19 
p=0.17 
8-iso 
 
r=0.35 
p=0.009 
 
r=0.04 
p=0.76 
r=0.34 
p=0.01 
LTC4 
 
 
r=0.16 
p=0.25 
r=0.06 
p=0.68 
r=0.17 
p=0.22 
IL-8 
 
 
r=-0.19 
p=0.18 
r=0.08 
p=0.56 
r=-0.18 
p=0.20 
ECP 
 
r=0.12 
p=0.40 
r=0.23 
p=0.10 
 
r=0.12 
p=0.39 
MPO 
 
 
r=-0.07 
p=0.61 
r=0.13 
p=0.37 
r=-0.07 
p=0.63 
 All correlations Spearman Rank  46 
 47 
 48 
  49 
e-Table 5: Sputum Inflammatory Mediators across different GINA Categories  50 
 51 
 
Inflammatory 
Mediators in Sputum 
GINA Control  
P-value Controlled Partly 
Controlled 
Uncontrolled 
Median 
(range) 
Median 
(range) 
Median 
(range) 
LTB4 (pg/ml) 1030.6 970.4 718.8 0.437 
 (432-3280) (240.4-6732) (278.4-2805)  
PGE2 (pg/ml) 2235 2353.5 2288.5 0.681 
 (832-3827) (103.4-5968) (33.4-6032)  
8-iso (pg/ml) 45.3 55.8 59.9 0.815 
 (21.4-111.4) (18.8-700) (16.4-373.6)  
LTC-4 (pg/ml) 424.4 475.2 342.8 0.334 
 (75.6-1783) (8.0-2664) (38.0-2624)  
IL-8 (pg/ml) 685.2 522.4 946.3 0.116 
 (43.6-3532) (8.8-4400) (4.40-4400)  
ECP (ng/ml) 36.0 53.60 106.8 0.163 
 (4.4-170) (1.20-220) (4.8-220)  
MPO (ng/ml) 96.8 87.75 166.4 0.863 
 (23.2-260) (0.80-506) (4.30-446.4)  
 52 
